Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $24.00 target price on the stock.

Several other equities analysts have also recently weighed in on CMPX. Wedbush restated an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Piper Sandler assumed coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective for the company. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. Guggenheim reiterated a "buy" rating and set a $12.00 target price on shares of Compass Therapeutics in a research note on Wednesday, April 2nd. Finally, Jefferies Financial Group raised their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Compass Therapeutics presently has an average rating of "Buy" and a consensus price target of $13.38.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock traded down $0.05 during midday trading on Monday, reaching $2.03. 67,530 shares of the company's stock traded hands, compared to its average volume of 866,736. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The company's 50 day simple moving average is $2.28 and its 200 day simple moving average is $2.09. The company has a market cap of $280.02 million, a price-to-earnings ratio of -5.47 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). As a group, equities research analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current year.

Insider Activity

In other news, insider Jonathan Anderman bought 20,000 shares of Compass Therapeutics stock in a transaction dated Monday, April 7th. The shares were bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now owns 21,000 shares of the company's stock, valued at approximately $32,340. This trade represents a 2,000.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the company's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. Corporate insiders own 28.50% of the company's stock.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after acquiring an additional 12,917 shares during the last quarter. Independent Advisor Alliance bought a new position in Compass Therapeutics in the 4th quarter valued at $26,000. BNP Paribas Financial Markets acquired a new position in Compass Therapeutics in the fourth quarter worth $27,000. Mariner LLC bought a new stake in shares of Compass Therapeutics during the fourth quarter worth $30,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at $35,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.